[
    "{\"step_by_step_thinking\": \"Golimumab is a monoclonal antibody that inhibits TNF-\u03b1, which is involved in the inflammatory response of sarcoidosis. However, according to Document [0] and Document [2], golimumab has failed to show any benefit in those with pulmonary sarcoidosis. Document [1] also supports this, stating that although treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis. Therefore, based on these documents, golimumab is not effective for sarcoidosis.\", \"answer_choice\": \"B. no\"}"
]